Arcutis Biotherapeutics Management
Management criteria checks 2/4
Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 8.33 years. total yearly compensation is $4.94M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $5.36M. The average tenure of the management team and the board of directors is 2.5 years and 4 years respectively.
Key information
Frank Watanabe
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 12.8% |
| CEO tenure | 8.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis
Sep 26Arcutis Biotherapeutics: A Name To Accumulate
Sep 18Arcutis acquires privately-held biotech Ducentis BioTherapeutics
Sep 07Arcutis launches plaque psoriasis therapy Zoryve in US
Aug 10Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Aug 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$5m | US$634k | -US$262m |
| Sep 30 2023 | n/a | n/a | -US$268m |
| Jun 30 2023 | n/a | n/a | -US$331m |
| Mar 31 2023 | n/a | n/a | -US$327m |
| Dec 31 2022 | US$5m | US$590k | -US$311m |
| Sep 30 2022 | n/a | n/a | -US$311m |
| Jun 30 2022 | n/a | n/a | -US$260m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$4m | US$525k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$3m | US$442k | -US$136m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$63m |
| Dec 31 2019 | US$1m | US$390k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$634k | US$327k | -US$19m |
Compensation vs Market: Frank's total compensation ($USD4.94M) is above average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Watanabe (55 yo)
8.3yrs
Tenure
US$4,935,266
Compensation
Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.3yrs | US$4.94m | 0.53% $ 5.4m | |
| Co-Founder & Independent Director | no data | US$153.74k | 0.77% $ 7.9m | |
| Senior VP & Chief Medical Officer | 3.8yrs | US$1.67m | 0.015% $ 149.0k | |
| Senior VP & Chief Commercial Officer | less than a year | US$2.03m | no data | |
| Senior VP & Chief Financial Officer | less than a year | no data | no data | |
| Chief Digital & Technology Officer | 2.6yrs | no data | no data | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| VP and Chief Compliance Officer & Privacy Officer | 3.3yrs | no data | no data | |
| Senior VP | 2.3yrs | US$5.14m | 0.0093% $ 94.8k | |
| Head of Corporate Communications | 2.8yrs | no data | no data | |
| Head of Marketing & Market Access | less than a year | no data | no data | |
| Vice President of Sales | 1.3yrs | no data | no data |
2.5yrs
Average Tenure
55yo
Average Age
Experienced Management: ARQT's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$4.94m | 0.53% $ 5.4m | |
| Co-Founder & Independent Director | 8.1yrs | US$153.74k | 0.77% $ 7.9m | |
| Independent Chairman of the Board | 8.1yrs | US$181.24k | 0.024% $ 247.5k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 3.5yrs | US$148.74k | no data | |
| Independent Director | 4yrs | US$148.74k | no data | |
| Director | 3.8yrs | US$144.24k | 0.17% $ 1.7m | |
| Independent Director | 2.9yrs | US$163.74k | 0.00026% $ 2.7k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
4.0yrs
Average Tenure
59.5yo
Average Age
Experienced Board: ARQT's board of directors are considered experienced (4 years average tenure).